Efficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203)
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz283.026
Abstract: Abstract Background Leiomyosarcoma (LMS) is one of the most common pathologic subtypes of soft tissue sarcoma (STS) with limited treatment options. An earlier analysis in ALTER0203 showed efficacy and safety of anlotinib in overall subtype… read more here.
Keywords: efficacy safety; analysis; safety; subgroup analysis ... See more keywords
The clinical activity and safety of anlotinib combined with anti-PD-1 antibodies in patients with advanced solid tumors.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e15081
Abstract: e15081Background: Anlotinib (AL3818) is a novel multi-target tyrosine kinase inhibitor (TKI) for tumor angiogenesis and tumor cell proliferation. Modulation of vascular endothelial growth factor-me... read more here.
Keywords: clinical activity; activity safety; anlotinib combined; combined anti ... See more keywords
Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Management and Research"
DOI: 10.2147/cmar.s304838
Abstract: Background Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The ALTER 0303 study has suggested that anlotinib improved overall survival (OS) and… read more here.
Keywords: efficacy safety; patients advanced; study; safety anlotinib ... See more keywords
The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.711704
Abstract: Objective: Refractory or recurrent pediatric solid tumors lack effective treatments, and are associated with dismal outcomes. Hence, there is an urgent need for a novel therapeutic strategy. This study aimed to evaluate the efficacy and… read more here.
Keywords: refractory recurrent; safety anlotinib; solid tumors; efficacy safety ... See more keywords